Tab Application Banner
  • Users Online: 161
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2017  |  Volume : 12  |  Issue : 6  |  Page : 149-155

Biomarkers in scleroderma: Current status

1 Division of Rheumatology, Perelman School of Medicine, University of Philadelphia, Philadelphia, PA, USA
2 Department of Medicine, BJ Medical College, Pune, Maharashtra, India
3 Department of Rheumatology and Clinical Immunology, Starcare Hospital, Kozhikode, Kerala, India

Correspondence Address:
Sukesh Edavalath
Department of Rheumatology and Clinical Immunology, Starcare Hospital, Kozhikode - 673 017, Kerala
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0973-3698.219087

Rights and Permissions

Scleroderma is an autoimmune disease characterized by indolent obliterative vasculopathy and widespread fibrosis. The two main morphological manifestations of the disease overlap and may make it difficult to separate activity from damage. Many patients, especially those with the limited subset of the disease, have an indolent course without clear-cut inflammatory manifestations. There is a felt need for validated biomarkers, which can differentiate activity from damage, and yet be sensitive to change with therapy. Multiplex arrays of biomarkers have ushered an era of targeted or personalized medicine based on phenotypic characteristics in an individual.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded586    
    Comments [Add]    

Recommend this journal